Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology. They are focused on delivering important new therapies to the millions of patients living with chronic skin conditions.
The company’s portfolio of dermatology therapeutics includes DRM01, a topical sebum inhibitor for acne; DRM02, a topical PDE4 inhibitor for inflammatory skin diseases; DRM04, a topical treatment for hyperhidrosis; and DRM05, a topical photodynamic therapy for acne. Dermira completed an initial public offering in October 2014.